Gene · 5602
MAPK10: mitogen-activated protein kinase 10
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. MAPK10: mitogen-activated protein kinase 10. Genes, record 5602. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5602
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P53779 | Mitogen-activated protein kinase 10 | 464 | 65 | Ensembl, GeneID, HGNC |
Source UniProt
Patents39
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 53916 | P53779 | Espacenet |
| JP 2025524002 A | 2025-07-25 | 36 | P53779 | Espacenet |
| KR 1020250039465 A | 2025-03-20 | 36 | P53779 | Espacenet |
| JP 2024023699 A | 2024-02-21 | 36 | P53779 | Espacenet |
| JP 2024505890 A | 2024-02-08 | 36 | P53779 | Espacenet |
| US 11708396 B2 | 2023-07-25 | 1750 | P53779 | Espacenet |
| JP 2023509886 A | 2023-03-10 | 36 | P53779 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 52354 | P53779 | Espacenet |
| KR 1020220123023 A | 2022-09-05 | 36 | P53779 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 155325 | P53779 | Espacenet |
1 to 10 of 39
See all 39 patentsDrugs5
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BENTAMAPIMOD | CHEMBL3545213 | c-Jun N-terminal kinase, JNK inhibitor | INHIBITOR | ChEMBL |
| BRIMAPITIDE | CHEMBL4297650 | c-Jun N-terminal kinase 3 inhibitor | INHIBITOR | ChEMBL |
| BRIMAPITIDE, C-TERMINAL ACID | CHEMBL4297348 | c-Jun N-terminal kinase 3 inhibitor | INHIBITOR | ChEMBL |
| CC-401 | CHEMBL1614713 | c-Jun N-terminal kinase 3 inhibitor | INHIBITOR | ChEMBL |
| TANZISERTIB | CHEMBL1950289 | c-Jun N-terminal kinase 3 inhibitor | INHIBITOR | ChEMBL |
Trials8
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT02809118 | BRIMAPITIDE, C-TERMINAL ACID | PHASE3 | 2020-08-07 | ClinicalTrials.gov |
| NCT02561091 | BRIMAPITIDE, C-TERMINAL ACID | PHASE3 | ClinicalTrials.gov | |
| NCT02235272 | BRIMAPITIDE | PHASE3 | ClinicalTrials.gov | |
| NCT01630252 | BENTAMAPIMOD | PHASE2 | ClinicalTrials.gov | |
| NCT01466725 | TANZISERTIB | PHASE2 | ClinicalTrials.gov | |
| NCT01203943 | TANZISERTIB | PHASE2 | ClinicalTrials.gov | |
| NCT00802425 | BRIMAPITIDE, C-TERMINAL ACID | PHASE2 | ClinicalTrials.gov | |
| NCT00126893 | CC-401 | PHASE1 | ClinicalTrials.gov |
NIH grants1,503
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MAPK10 papers | Newest fiscal year |
|---|---|---|---|
| R01EY011500 | Structure-function studies of visual arrestin | 34 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| R01HL016037 | Molecular Regulation of Cardiovascular 7 TM Receptors | 7 | 2025 |
| P20GM103474 | MT INBRE: A Multidisciplinary Research Network | 5 | 2025 |
| R01GM120569 | Molecular basis for arrestin-mediated signaling | 5 | 2025 |
| R01GM086858 | New Molecular Probes For Protein Kinases | 4 | 2025 |
| R01NS094402 | Regulation of Axonal Signaling by Palmitoylation | 4 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 3 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 3 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 3 | 2025 |
1 to 10 of 1,503Source NIH's project files
See all 1,503 nih grantsPapers2,569
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-objective-conditioned-return-blocks decision transformer: a novel approach for multi-objective de novo drug design. | Bioinformatics | 2026 | 42826505 | PubTator, text mining | PubMed |
Corrigendum to 'Aptamer engineering exosomes loaded on biomimetic periosteum to promote angiogenesis and bone regeneration by targeting injured nerves via JNK3 MAPK pathway' [Mater. Today Bio 16 (2022) 100434]. | Mater Today Bio | 2026 | 42807142 | PubTator, text mining | PubMed |
| The MAPK signalling landscape of Leishmania: structural diversity, biological functions and therapeutic potential. | Biochimie | 2026 | 42749182 | PubTator, text mining | PubMed |
| Advances in N- and S-Heterocycles as c-Jun-N-Terminal Kinase 3 Inhibitors for Alzheimer's Disease Treatment. | Drug Dev Res | 2026 | 42747078 | PubTator, text mining | PubMed |
| Multi-Property De Novo Drug Design Using Deep Learning-Based Knowledge Distillation and Reinforcement Learning. | Int J Mol Sci | 2026 | 42511472 | PubTator, text mining | PubMed |
| Corrigendum to: Identification of Pharmacophore Responsible for the JNK3 Enzyme Inhibition using KPLS-based QSAR Analysis. | Cent Nerv Syst Agents Med Chem | 2026 | 42494105 | PubTator, text mining | PubMed |
| Selective JNK3 Inhibition Ameliorates TGF- β -Mediated Glomerular Injury and Fibrosis in the Kidneys. | J Am Soc Nephrol | 2026 | 42440378 | PubTator, text mining | PubMed |
| Single-cell RNA sequencing and cross-species analysis revealed the role of T cell-driven inflammatory responses in the pathogenesis of aortic dissection. | BMC Cardiovasc Disord | 2026 | 42436415 | PubTator, text mining | PubMed |
| Polypharmacological Targeting of G2019S Mutant LRRK2 and JNK3 for the Discovery of a Lead Compound against Parkinson's Disease. | J Med Chem | 2026 | 42329175 | PubTator, text mining | PubMed |
| RAS pathway activity subtypes identified by machine learning define prognostic and immune microenvironment characteristics in lung adenocarcinoma. | Discov Oncol | 2026 | 42207441 | PubTator, text mining | PubMed |
1 to 10 of 2,569
See all 2,569 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5602
GET https://conductscience.org/api/genes/v1/5602/patents?page=2